134 related articles for article (PubMed ID: 31067142)
61. A review of cervical cancer patients presenting in Harare and Parirenyatwa Hospitals in 1998.
Chirenje ZM; Rusakaniko S; Akino V; Mlingo M
Cent Afr J Med; 2000 Oct; 46(10):264-7. PubMed ID: 11682933
[TBL] [Abstract][Full Text] [Related]
62. Doppler Ultrasound Flow Evaluation of the Uterine Arteries Significantly Correlates with Tumor Size in Cervical Cancer Patients.
Bolla D; In-Albon S; Papadia A; Di Naro E; Gasparri ML; Mueller MM; Raio L
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S959-63. PubMed ID: 26036189
[TBL] [Abstract][Full Text] [Related]
63. Preoperative Chemoradiotherapy in Locally Advanced Bulky Squamous Cell Carcinoma of the Uterine Cervix.
Nakao Y; Hashiguchi M; Nishiyama S; Aihara S; Iwasaka T; Yokoyama M
Int J Gynecol Cancer; 2017 Nov; 27(9):1943-1948. PubMed ID: 28786876
[TBL] [Abstract][Full Text] [Related]
64. The adverse effect of treatment prolongation in cervical cancer by high-dose-rate intracavitary brachytherapy.
Chen SW; Liang JA; Yang SN; Ko HL; Lin FJ
Radiother Oncol; 2003 Apr; 67(1):69-76. PubMed ID: 12758242
[TBL] [Abstract][Full Text] [Related]
65. Recurrent and persistent squamous cell cervical carcinoma in women under age 35.
Stuart GC; Robertson DI; Fedorkow DM; Duggan MA; Nation JG
Gynecol Oncol; 1988 Jun; 30(2):163-72. PubMed ID: 3371740
[TBL] [Abstract][Full Text] [Related]
66. Definitive concurrent chemoradiotherapy in cervical cancer--a University of Malaya Medical Centre experience.
Zamaniah WI; Mastura MY; Phua CE; Adlinda A; Marniza S; Rozita AM
Asian Pac J Cancer Prev; 2014; 15(20):8987-92. PubMed ID: 25374241
[TBL] [Abstract][Full Text] [Related]
67. Inverse Planned High-Dose-Rate Brachytherapy for Locoregionally Advanced Cervical Cancer: 4-Year Outcomes.
Tinkle CL; Weinberg V; Chen LM; Littell R; Cunha JAM; Sethi RA; Chan JK; Hsu IC
Int J Radiat Oncol Biol Phys; 2015 Aug; 92(5):1093-1100. PubMed ID: 26194683
[TBL] [Abstract][Full Text] [Related]
68. Concurrent chemoradiotherapy for non-bulky stage IB/II cervical cancer without pelvic node enlargement.
Wakayama A; Inamine M; Kudaka W; Nagai Y; Nakamoto T; Ooyama T; Ariga T; Kasuya G; Toita T; Aoki Y
Anticancer Res; 2013 Nov; 33(11):5123-6. PubMed ID: 24222159
[TBL] [Abstract][Full Text] [Related]
69. Neoadjuvant Platinum-based Chemotherapy Followed by Radical Hysterectomy for Stage Ib2-IIb Adenocarcinoma of the Uterine Cervix - An Italian Multicenter Retrospective Study.
Gadducci A; Landoni F; Cosio S; Zizioli V; Zola P; Ferrero AM; Lapresa MT; Maggino T; Sartori E
Anticancer Res; 2018 Jun; 38(6):3627-3634. PubMed ID: 29848719
[TBL] [Abstract][Full Text] [Related]
70. Pathologic characteristics, type of treatment and follow up of patients with uterine cervical carcinoma referred to the Radiation Oncology Department, Cancer Institute, Imam Khomeini Hospital,Tehran, Iran, 1995-2001.
Farnaz AH; Ebrahim E; Bita K
Asian Pac J Cancer Prev; 2008; 9(1):86-8. PubMed ID: 18439082
[TBL] [Abstract][Full Text] [Related]
71. Contributing factors for bone metastasis in uterine cervical cancer.
Yoon A; Choi CH; Kim HJ; Park JY; Lee YY; Kim TJ; Lee JW; Bae DS; Kim BG
Int J Gynecol Cancer; 2013 Sep; 23(7):1311-7. PubMed ID: 23839246
[TBL] [Abstract][Full Text] [Related]
72. Pharmacokinetic analysis of DCE-MRI data of locally advanced cervical carcinoma with the Brix model.
Lund KV; Simonsen TG; Kristensen GB; Rofstad EK
Acta Oncol; 2019 Jun; 58(6):828-837. PubMed ID: 30810443
[No Abstract] [Full Text] [Related]
73. [Curative effect analysis of postoperative concurrent chemoradiotherapy on early-stage cervical cancer patients with intermediate-risk factors].
Tang Q; Tu YQ; Chen JH; Lyu XJ; Yan DD
Zhonghua Zhong Liu Za Zhi; 2018 Jun; 40(6):462-466. PubMed ID: 29936774
[No Abstract] [Full Text] [Related]
74. Chemoradiation for invasive cervical cancer in elderly patients: outcomes and morbidity.
Goodheart M; Jacobson G; Smith BJ; Zhou L
Int J Gynecol Cancer; 2008; 18(1):95-103. PubMed ID: 17466049
[TBL] [Abstract][Full Text] [Related]
75. Outcome and prognostic factors in cervical cancer patients treated with surgery and concurrent chemoradiotherapy: a retrospective study.
Liu YM; Ni LQ; Wang SS; Lv QL; Chen WJ; Ying SP
World J Surg Oncol; 2018 Jan; 16(1):18. PubMed ID: 29378625
[TBL] [Abstract][Full Text] [Related]
76. Ten Years’ Survival in Patients with Cervical Cancer and Related Factors in West Azerbaijan Province: Using of Cox Proportion Hazard Model.
Khalkhali HR; Gharaaghaji R; Valizadeh R; Kousehlou Z; Ayatollahi H
Asian Pac J Cancer Prev; 2019 May; 20(5):1345-1351. PubMed ID: 31127888
[TBL] [Abstract][Full Text] [Related]
77. Prognostic value of pretreatment 18F-fluorodeoxyglucose uptake in patients with cervical cancer treated with definitive chemoradiotherapy.
Onal C; Reyhan M; Parlak C; Guler OC; Oymak E
Int J Gynecol Cancer; 2013 Jul; 23(6):1104-10. PubMed ID: 23792605
[TBL] [Abstract][Full Text] [Related]
78. [Isolated pelvic recurrences of cervical carcinoma treated with salvage chemoradiotherapy].
Besson N; Touboul E; Daraï É; Lefranc JP; Monnier L; Schlienger M; Huguet F
Cancer Radiother; 2014 Mar; 18(2):83-8. PubMed ID: 24462252
[TBL] [Abstract][Full Text] [Related]
79. Risk factors for pelvic and distant recurrence in locally advanced cervical cancer.
Queiroz ACM; Fabri V; Mantoan H; Sanches SM; Guimarães APG; Ribeiro ARG; da Nogueira Silveira Lima JP; Chen MJ; Baiocchi G; da Costa AABA
Eur J Obstet Gynecol Reprod Biol; 2019 Apr; 235():6-12. PubMed ID: 30771718
[TBL] [Abstract][Full Text] [Related]
80. Chemoradiation in cervical cancer with cisplatin and high-dose rate brachytherapy combined with external beam radiotherapy. Results of a phase-II study.
Strauss HG; Kuhnt T; Laban C; Puschmann D; Pigorsch S; Dunst J; Koelbl H; Haensgen G
Strahlenther Onkol; 2002 Jul; 178(7):378-85. PubMed ID: 12163992
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
